Sanofi reports profit increase

Article Abstract:

Sanofi S.A. of France posted net income for the first quarter of 1.51 billion Euros ($1.92 billion). Revenues were due to strong vaccine sales despite increased competition from generic drug companies. The pharmaceutical giant is still integrating costs from the Aventis merger.

Author: Whalen, Jeanne, Fontaine, Laetitia
Sanofi S.A., Company overview

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Sanofi stands by sleeping pill's safety profile

Article Abstract:

Sanofi-Aventis S.A. of France has reviewed research and says it will stand by its sleeping medication "Ambien." There were renewed concerns about the side effect of somnambulism. The pharmaceutical giant said it has found no reason to change the safety profile of the drug.

Author: Whalen, Jeanne
Product information, Sedatives, Hypnotics and sedatives, Hypnotics

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Plavix sales brighten Sanofi's view

Article Abstract:

Fourth-quarter net income for French pharmaceutical firm Sanofi-Aventis S.A. increased 31% to $1.09 bil, while full-year sales in the US reached $4.07 bil. The firm announced a positive forecast, due in part to Plavix, its best-selling drug.

Author: Whalen, Jeanne
Forecasts, trends, outlooks, Company business forecast/projection, Company forecasts, Financial report

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Pharmaceutical industry, France, Company sales and earnings, Company earnings/profit, SNY, Sanofi-Aventis S.A.
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.